Boehringer Ingelheim Venture Fund
Ingelheim am Rhein, GermanyFounded 2010
The Boehringer Ingelheim Venture Fund (BIVF) is the corporate venture capital arm of Boehringer Ingelheim, investing in groundbreaking therapeutics-focused biotechnology companies to drive innovation in biomedical research across immuno-oncology, regenerative medicine, and infectious diseases.
38% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (2 deals in the last 12 months vs 5 prior). Average disclosed round size is $33.6M (across 27 rounds with reported amounts).
Portfolio
54
Fund Size
—
Top Stage
Series A
Last 12 Mo
2
Team
Kevin White
Investment Manager
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
84 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Centauri Therapeutics | Series A | — | Feb 2026 |
 STRM.BIO | Seed | $8M | Jan 2026 |
 Nuevocor | Series B | $45M | May 2025 |
 Brainomix | Series C | $18M | Mar 2025 |
| Nuevocor | Series B | $45M | Jan 2025 |
| RRefoxy Pharmaceuticals | Seed | $10M | Dec 2024 |
 Glox Therapeutics | Unknown | — | Nov 2024 |
 AIgnostics | Series B | $34M | Oct 2024 |
 Asgard Therapeutics | Series A | — | Mar 2024 |
 Ilara Health | Seed | $4.2M | Feb 2024 |
 HepaRegeniX | Series C | — | Jan 2024 |
 Refoxy Pharma | Seed | — | Jan 2024 |
 Obulytix | Seed | — | Dec 2023 |
| Glox Therapeutics | Seed | — | Nov 2023 |
 DiogenX | Series A | $33.5M | Oct 2023 |
| AAgomab | Series B | $100M | Oct 2023 |
 Otto | Series B | $43M | Aug 2023 |
 C Mo Medical Solutions | Unknown | — | Jan 2023 |
| DiogenX | Series A | — | Jan 2023 |
| RRgenta | Series A | $52M | Nov 2022 |
| AIgnostics | Series A | — | Sep 2022 |
| C Mo Medical Solutions | Unknown | — | Sep 2022 |
| IImCheck Therapeutics | Series C | — | Jun 2022 |
| C Mo Medical Solutions | Seed | — | Jan 2022 |
| Brainomix | Series B | $16M | Dec 2021 |
Page 1 of 4
Top Co-Investors
High-Tech Gründerfonds27 shared
Andera Partners9 shared
Kurma Partners7 shared
coparion6 shared
Forbion6 shared
Takeda Ventures, Inc.6 shared
Vi Partners6 shared
Wellington Management5 shared
Omnes Capital5 shared
EQT Life Sciences5 shared
Gimv5 shared
NRW.BANK5 shared
Sofinnova Partners5 shared
RA Capital Management4 shared
Versant Ventures4 shared
Novo Holdings A/S4 shared
Pfizer Ventures4 shared
Portugal Ventures4 shared
Last updated: 20 October 2026